HomeCONGRESS

CONGRESS

View Category
Day 3

POSEIDON: Transendocardial infusion of autologous vs. allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy.

Safety and efficacy of autologous vs. allogeneic mesenchymal stem cells had not yet been compared. This trial...
solaci -
Learn More
Day 3

SCIPIO trial: Intracoronary infusion of autologous cardiac stem cells improve ventricular function.

This is the first trial that used autologous cardiac stem cells for the treatment of ischemic cardiomyopathy....
solaci -
Learn More
Day 3

ALCADIA: An intra-myocardial injection of autologous cardiac derived stem cells improves ventricular function in patients with ischemic cardiomyopathy.

This is an open trial that included 7 patients with ischemic cardiomyopathy and reduced the ejection fraction...
solaci -
Learn More
Day 1

TACT trial: Chelation Therapy for the Treatment of Coronary Disease.

In theory, also as for certain diseases caused by mineral deposits, Chelation treatment with EDTA (Ethylene Diamine...
solaci -
Learn More
Day 1

TRILOGY Trial: First large scale test evaluating platelet function in acute coronary syndromes.

TRILOGY ACS which was presented at the ESC 2012 is a randomized, double blind study that included...
solaci -
Learn More
Day 1

FREEDOM trial: CABG versus angioplasty treatment for diabetic patients with multivessel disease

The trial included 1,900 patients followed for at least 2 years, (mean 3.8 years), randomized 1:1 to...
solaci -
Learn More
Day 2

DALCETRAPIB: Dalcetrabib for the treatment of ACS

High levels of HDL are known to exert a protective effect. In previous studies, dalcetrapib administration increased...
solaci -
Learn More
Day 2

Monoclonal antibodies for the treatment of dislipidemia in patients on maximal dose statins.

Statins are first-line therapy for hypercholesterolemia. However, many patients are not able to achieve their goals despite...
solaci -
Learn More